PT Indofarma Tbk (IDX:INAF)
Indonesia · Delayed Price · Currency is IDR 126.00
0.00 (0.00%)
Jul 1, 2024, 2:55 PM WIB
PT Indofarma Tbk Financials Overview
Financials in millions IDR. Fiscal year is January - December.
Millions IDR. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 163,566 | 151,551 | 210,380 | 523,599 | 980,371 | 2,901,987 |
Revenue Growth | -2.46% | -27.96% | -59.82% | -46.59% | -66.22% | 69.15% |
Gross Profit Gross Profit Growth | -911.34 | -19,305 | -42,102 | -158,896 | -15,302 | 442,875 |
Operating Income Operating Income Growth | -165,767 | -201,793 | -249,937 | -566,859 | -338,082 | 53,219 |
Net Income Net Income Growth | -67,567 | -77,989 | -334,489 | -720,993 | -457,624 | -37,581 |
Earnings Per Share EPS Growth | -21.80 | -25.16 | -107.93 | -232.63 | -147.66 | -12.13 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Medical Devices & Others Medical Devices & Others Growth | 71,748 | 104,223 | 181,532 | 424,219 | 802,101 |
Medicine Medicine Growth | 79,803 | 106,157 | 342,067 | 556,152 | 2,099,886 |
Total Total Growth | 151,551 | 210,380 | 523,599 | 980,371 | 2,901,987 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 4,403 | 5,686 | 10,114 | 17,071 | 269,751 | 380,814 |
Total Debt Total Debt Growth | 722,812 | 700,285 | 738,979 | 701,756 | 627,213 | 604,838 |
Net Cash (Debt) Net Cash Growth | -718,408 | -694,599 | -728,865 | -684,685 | -357,462 | -224,024 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -231.80 | -224.12 | -235.17 | -220.92 | -115.34 | -72.28 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -190,884 | -209,982 | -21,654 | -194,131 | -75,946 | 92,899 |
Capital Expenditures CapEx Growth | - | - | -50 | -4,738 | -12,468 | -21,270 |
Free Cash Flow Free Cash Flow Growth | -190,884 | -209,982 | -21,704 | -198,869 | -88,414 | 71,629 |
Free Cash Flow Growth | - | - | - | - | - | 100.92% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | -0.56% | -12.74% | -20.01% | -30.35% | -1.56% | 15.26% |
Operating Margin | -101.35% | -133.15% | -118.80% | -108.26% | -34.48% | 1.83% |
Pretax Margin | -36.89% | -47.15% | -134.88% | -127.87% | -56.03% | 0.30% |
Profit Margin | -41.31% | -51.46% | -158.99% | -137.70% | -46.68% | -1.29% |
FCF Margin | -116.70% | -138.56% | -10.32% | -37.98% | -9.02% | 2.47% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 276.67 | 276.67 | 276.67 | 276.67 | 276.67 |
P/FCF Ratio | - | - | - | - | - | 96.49 |
PS Ratio | 2.39 | 2.58 | 1.86 | 3.43 | 3.64 | 2.38 |